Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice

Neurology

Volumn 62, Issue 4, 2004, Pages 563-568

  Hall, Gillian C ^c   Brown, Martin M ^a   Mo, Jingping ^b   MacRae, Kenneth D ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PFIZER INC   (United States)

^c Grimsdyke House   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN AGONIST;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INFANT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MORTALITY; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; STROKE;

EID: 1342288364     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000110312.36809.7F     Document Type: Article

References (48)

1. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994;34(suppl 2):6-11.
2. Buring JE, Hebert P, Romero J, et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 1995;52:129-134.
3. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997;54:362-368.
4. Tzourio C, Iglesias S, Hubert JB, et al. Migraine and risk of ischaemic stroke: a case-control study. Br Med J 1993;307:289-292.
5. Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women. Associated risk factors. JAMA 1975;231:718-722.
6. Bogousslavsky J, Regli F, Van Melle G, Payot M, Uske A. Migraine stroke. Neurology 1988;38:223-227.
7. Rothrock JF, Walicke P, Swenson MR, Lyden PD, Logan WR. Migrainous stroke. Arch Neurol 1988;45:63-67.
8. Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Théroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med 1981;304:763-766.
9. Nakamura Y, Shinozaki N, Hirasawa M, et al. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina. Jpn Circ J 2000;64:239-242.
10. Leviton A, Malvea B, Graham JR. Vascular diseases, mortality, and migraine in the parents of migraine patients. Neurology 1974;24:669-672.
11. Merikangas KR. Comorbidity of migraine and other conditions in the general population of adults in the United States. Cephalalgia 1991; (suppl 11):108-109. Abstract.
12. Mitchell P, Wang JJ, Currie J, Cumming RG, Smith W. Prevalence and vascular associations with migraine in older Australians. Aust NZ J Med 1998;28:627-632.
13. Sternfeld B, Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology 1995;45:2135-2142.
14. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-546.
15. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993;87:401-405.
16. Dodick DW, Silberstein S, Dahlof CG. Is there a preferred triptan? Headache 2002;42:1-7.
17. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumnatriptan oesophageal in origin? Lancet 1994;344:985-986.
18. Foster JM, Houghton LA, Whorwell PJ, Morris J. Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Aliment Pharmacol Ther 1999;13:927-936.
19. Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 1994; 343:1105-1106.
20. Jayamaha JE, Street MK. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med 1995;21:82-83.
21. O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995;45:2274-2276.
22. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996;36:329-331.
23. Abbrescia VD, Pearlstein L, Kotler M. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. J Am Osteopath Assoc 1997;97:162-164.
24. Laine K, Raasakka T, Mäntynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache 1999;39:511-512.
25. O'Quinn S, Davis RL, Gutterman DL, Pait GD, Fox AW. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19:223-231.
26. Hall GC, Luscombe D, Walker SR. Post-marketing surveillance using a computerised general practice database. Pharm Med 1988;2:345-351.
27. Garcia Rodriguez LA, Perez Gutthan S. Use of the General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
28. The Read Codes, version 3. London: HMSO, 1996.
29. Oxmis Problem Codes for Primary Medical Care. Oxford: Oxmis Publications, 1978.
30. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000;161:5-8.
31. International Statistical Classification of Diseases and Related Health Problems, 10th rev, vol 2. Geneva: World Health Organization, 1993.
32. Stata statistical software [computer program]. College Station, TX. Stata Corp.
33. Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
34. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. Br Med J 1995;310:830-833.
35. Chang CL, Donaghy M, Poulter N, et al. Migraine and stroke in young women: case-control study. Br Med J 1999;318:13-18.
36. Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol 1989;42:773-780.
37. Carolei A, Marini C, De Matteis G, et al. History of migraine and risk of cerebral ischaemia in young adults. Lancet 1996;347:1503-1506.
38. Olesen J, Friberg L, Olsen TS, et al. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain 1993;116:187-202.
39. Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke 1999;30:1230-1233.
40. Senter HJ, Lieberman AN, Pinto R. Cerebral manifestations of ergotism. Report of a case and review of the literature. Stroke 1976;7:88-92.
41. Lafitte C, Even C, Henry-Lebras F, de Toffol B, Autret A. Migraine and angina pectoris by coronary artery spasm. Headache 1996;36:332-334.
42. Wayne VS. A possible relationship between migraine and coronary artery spasm. Aust NZ J Med 1986;16:708-710.
43. Waters WE, Campbell MJ, Elwood PC. Migraine, headache, and survival in women. Br Med J 1983;287:1442-1443.
44. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-69.
45. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992;152:1273-1278.
46. Dowson A, Jagger S. The UK migraine patient survey: quality of life and treatment. Curr Med Res Opin 1999;15:241-253.
47. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998;38:87-96.
48. Velez Roa S, Preumont N, Mols P, Stoupel E, Renard M. Ventricular fibrillation secondary to ergotamine in a healthy young woman. Acta Cardiol 1999;54:283-286.